Medtronic (MDT)

Get paid a real income now on your Intuitive Surgical shares—income you keep no matter what—in exchange for agreeing to sell at a higher price if the stock gets there.

Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years.

Oppenheimer argues Ottava and Hugo pose no near-term threat to da Vinci

Bill Shields, who led transcatheter mitral and tricuspid therapies at Medtronic, has joined Versa Vascular, developer of a valve repair treatment.

Medtronic stock has delivered a 20.8% gain over the past three years, yet current checks suggest it now sits close to its estimated intrinsic value rather than at a clear discount. At the same time, e...